Mukka Proteins Limited has informed the Exchange about Investor Presentation
MUKKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mukka Proteins filed its Q3 & 9M FY26 investor presentation. 9MFY26 revenue from operations stood at ₹1,068.9 Cr, up ~71% from ₹624.8 Cr in 9MFY25, with 9M EBITDA of ₹96.2 Cr vs ₹78.7 Cr and PAT of ₹35.7 Cr vs ₹34.1 Cr. Quarterly performance showed notable margin expansion, with Q3 FY26 EBITDA margin improving sharply versus Q3 FY25 levels. Key strategic updates include a ₹474.89 Cr 4-year order from Bengaluru Solid Waste Management Ltd (BSWML) for legacy leachate treatment, board-approved 100% acquisition of Ento Proteins and Haris Marine Products, and Verra registration of a 300 TPD BSF (insect protein) project. Management reiterated a target of ₹2,500+ Cr revenue by FY30 (from ₹887 Cr in FY25) driven by four verticals: fish protein, insect protein, waste management, and frozen seafood, with 75.7% of 9M revenue from exports across 25+ countries.
Strong revenue growth and margin expansion signal improving operating leverage, while the ₹475 Cr government order and insect protein carbon credit progress provide multi-year earnings visibility. Shareholders should note the ambitious 2.8x revenue target by FY30 is contingent on successful execution of waste management, insect protein scaling, and further acquisitions, which carry integration and execution risks.